104 related articles for article (PubMed ID: 8832109)
1. Identification and characterization of a 14 kDa immunosuppressive protein derived from IIB-MEL-J, a human melanoma cell line.
Morvillo V; Bover L; Mordoh J
Cell Mol Biol (Noisy-le-grand); 1996 Jul; 42(5):779-95. PubMed ID: 8832109
[TBL] [Abstract][Full Text] [Related]
2. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta is not the major soluble immunosuppressor in the microenvironments of human breast tumours.
Xie J; Gallagher G
Anticancer Res; 1992; 12(6B):2117-21. PubMed ID: 1295457
[TBL] [Abstract][Full Text] [Related]
4. In vitro immunization of human B lymphocytes with cultured melanoma cells (SK-MEL 28).
Zhang XM; Borrebaeck CA
Hum Antibodies Hybridomas; 1990; 1(1):42-6. PubMed ID: 1966473
[TBL] [Abstract][Full Text] [Related]
5. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of interleukin 2 production by factors released from tumor cells.
Hersey P; Bindon C; Czerniecki M; Spurling A; Wass J; McCarthy WH
J Immunol; 1983 Dec; 131(6):2837-42. PubMed ID: 6605993
[TBL] [Abstract][Full Text] [Related]
7. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
[TBL] [Abstract][Full Text] [Related]
8. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
[TBL] [Abstract][Full Text] [Related]
10. Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient.
Doucet C; Meazza R; Pottin-Clemenceau C; Scudeletti M; Brouty-Boye D; Ferrini S; Alileche A; Taoufik Y; Jasmin C; Azzarone B; Indiveri F
Melanoma Res; 1997 Aug; 7 Suppl 2():S7-17. PubMed ID: 9578412
[TBL] [Abstract][Full Text] [Related]
11. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice.
Mrowietz U; Schwenk U; Maune S; Bartels J; Küpper M; Fichtner I; Schröder JM; Schadendorf D
Br J Cancer; 1999 Mar; 79(7-8):1025-31. PubMed ID: 10098731
[TBL] [Abstract][Full Text] [Related]
12. Induction of inhibitory activity for B cell differentiation in human CD8 T cells with pokeweed mitogen, dimaprit, and cAMP upregulating agents: countersuppressive effect of platelet factor 4.
Crisi GM; Katz IR; Zucker MB; Thorbecke GJ
Cell Immunol; 1996 Sep; 172(2):205-16. PubMed ID: 8964082
[TBL] [Abstract][Full Text] [Related]
13. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
[TBL] [Abstract][Full Text] [Related]
14. Alpha-1 acid glycoprotein is an immunosuppressive factor found in ascites from ovaria carcinoma.
Elg SA; Mayer AR; Carson LF; Twiggs LB; Hill RB; Ramakrishnan S
Cancer; 1997 Oct; 80(8):1448-56. PubMed ID: 9338469
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic resistance: characterization and inactivation by specific antiserum of a putative protein family produced by tumour cells.
Zhou S; Li W; Hill HZ; Hill GJ; Kueppers F; McKenna WG; Muschel RJ; Wolansky LJ; Silva HC
Melanoma Res; 1999 Feb; 9(1):40-50. PubMed ID: 10338333
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients.
Tamura K; Shibata Y; Matsuda Y; Ishida N
Cancer Res; 1981 Aug; 41(8):3244-52. PubMed ID: 6166371
[TBL] [Abstract][Full Text] [Related]
17. Identification with monoclonal antibody 140.240 of a structural variant of melanotransferrin shed by human melanoma cell lines in vitro.
Liao SK
Anticancer Res; 1996; 16(1):171-6. PubMed ID: 8615605
[TBL] [Abstract][Full Text] [Related]
18. Factor VIII concentrates and the immune system--laboratory investigations.
Wadhwa M; Barrowcliffe TW; Mire-Sluis AR; Thorpe R
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S65-79. PubMed ID: 7495973
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
20. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
